NCT03621904Recruiting
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 18 Jan 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 6 Aug 2018
- Start date
- 15 Oct 2022
- Primary completion date
- 15 Oct 2026
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Endometrial cancer
- NCT number
- NCT03621904
What you commit to
- Study type: Observational
- Planned participants: 150
- From 15 Oct 2022 to the primary completion date, 15 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adjuvant hormonal therapy started following complete resection of endometrial carcinoma
- Synchronous use of hormonal therapy for other indications
Other
- Endometrial sarcoma or endometrial stroma cell sarcoma
Who the study is looking for
- Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
- All histologic types of endometrial carcinoma
- Planned treatment with any type of hormonal therapy
- Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.
Age in the registry: 18 years to 110 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.